Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study

(2018) Mikhail Kosiborod et al.   DIABETES OBESITY & METABOLISM

Risk of Amputations Associated with SGLT2 Inhibitors Compared to DPP-4 Inhibitors: A Propensity-Matched Cohort Study

(2018) Sruthi Adimadhyam et al.   DIABETES OBESITY & METABOLISM

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

(2018) Karin Rådholm et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

(2018) Mikhail Kosiborod et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

(2018) Elisabetta Patorno et al.   BMJ-British Medical Journal

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

(2018) Elisabetta Patorno et al.   BMJ-British Medical Journal

All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database

(2017) Konstantinos A. Toulis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

(2017) Kåre I Birkeland et al.   Lancet Diabetes & Endocrinology

Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor

(2017) Jacob A. Udell et al.   CIRCULATION

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice

(2016) Angelo Avogaro et al.   Cardiovascular Diabetology

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Real-World Evidence — What Is It and What Can It Tell Us?

(2016) Rachel E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis

(2014) William L. Baker et al.   Journal of the American Society of Hypertension

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case Definitions for Acute Myocardial Infarction in Administrative Databases and Their Impact on In-Hospital Mortality Rates

(2012) Amy Metcalfe et al.   HEALTH SERVICES RESEARCH

A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent

(2012) Bruce Fireman et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY